1,076 reports of this reaction
2.1% of all OXYBUTYNIN reports
#8 most reported adverse reaction
PAIN is the #8 most commonly reported adverse reaction for OXYBUTYNIN, manufactured by Allergan, Inc.. There are 1,076 FDA adverse event reports linking OXYBUTYNIN to PAIN. This represents approximately 2.1% of all 51,990 adverse event reports for this drug.
OXYBUTYNIN has an overall safety score of 78 out of 100. Patients taking OXYBUTYNIN who experience pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PAIN is a less commonly reported adverse event for OXYBUTYNIN, but still significant enough to appear in the safety profile.
In addition to pain, the following adverse reactions have been reported for OXYBUTYNIN:
The following drugs have also been linked to pain in FDA adverse event reports:
PAIN has been reported as an adverse event in 1,076 FDA reports for OXYBUTYNIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
PAIN accounts for approximately 2.1% of all adverse event reports for OXYBUTYNIN, making it a notable side effect.
If you experience pain while taking OXYBUTYNIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.